Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis

Proteins: Structure, Function and Bioinformatics

Volumn 77, Issue 1, 2009, Pages 84-96

  Forman, Julia R ^a,c   Worth, Catherine L ^a,d   Bickerton, G Richard J ^a,e   Eisen, Tim G ^b   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c INSTITUT PASTEUR   (France)

^d LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Biocomputing; Bioinformatics; Cancer; Genotype phenotype; Mutation; VHL

Indexed keywords

ELONGIN B; ELONGIN C; HYPOXIA INDUCIBLE FACTOR; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KIDNEY CARCINOMA; MISSENSE MUTATION; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; STRUCTURAL BIOINFORMATICS; THERMODYNAMICS; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; COMPUTATIONAL BIOLOGY; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION, MISSENSE; PHENOTYPE; PHEOCHROMOCYTOMA; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 70349318347     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22419     Document Type: Article

References (34)

1. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
2. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-1406.
3. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999;96:12436-12441. (Pubitemid 29513520)
4. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-661. (Pubitemid 29289593)
5. Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG, Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-1446.
6. Listzwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-1833. (Pubitemid 29353049)
7. Lonergan KM, Iliolpoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG, Jr. Regulation of the hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-741.
8. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997;94:2156-2161. (Pubitemid 27136844)
9. Stebbins CE, Kaelin WG, Jr, Pavletich NP. Structure of the VHL-elongin-C-elongin-B complex: implications for VHL tumor suppressor function. Science 1999;284:455-461. (Pubitemid 29289612)
10. Hon W-C, Wilson MI, Harlos K, Claridge TDW, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY. Structural basis for the recognition of hydroxyproline in HIF-1a by pVHL. Nature 2002;417:975-978. (Pubitemid 34716877)
11. Min J-H, Yang H, Ivan M, Gertler F, Kaelin WG, Jr, Pavletich NP. Structure of an HIF-1a-pVHL complex: hydroxyproline recognition in signaling. Science 2002;296:1886-1889. (Pubitemid 34596278)
12. Kaelin WG, Jr. Proline hydroxylation and gene expression. Annu Rev Biochem 2005;74:115-128.
13. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
14. Frew IJ, Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007;19:685-690.
15. Hes FJ, Luijt RBvd, Janssen ALW, Zewald RA, de Jong GJ, Lenders JW, Links TP, Luyten GPM, Sijmons RH, Eussen HJ, Halley DJJ, Lips CJM, Pearson PL, van den Ouweland AMW, Majoor-Krakauer DF. Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing. Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 2007;72:122-129.
16. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007;28:143-149. (Pubitemid 46233311)
17. Worth CL, Bickerton GRJ, Schreyer A, Forman JR, Cheng TMK, Lee S, Gong S, Burke DF, Blundell TL. A structural bioinformatics approach to the analysis of non-synonymous single nucleotide polymorphisms and their relation to disease. J Bioinform Comput Biol 2007;5:1297-1318.
18. Chelliah V, Chen L, Blundell TL, Lovell SC. Distinguishing structural and functional restraints in evolution in order to identify interaction sites. J Mol Biol 2004;342:1487-1504. (Pubitemid 39213963)
19. Topham CM, Srinivasan N, Blundell TL. Prediction of protein mutants based on structural environment-dependent amino acid substitution and propensity tables. Protein Eng 1997;10:7-21. (Pubitemid 27073347)
20. Smith RE, Lovell SC, Burke DF, Montalvao RW. Andante: reducing side-chain rotamer search space during comparative modelling using environment-specific substitution probabilities. Bioinformatics 2007;23:1099-1105.
21. Worth CL, Burke DF, Blundell TL. Estimating the effects of single nucleotide polymorphisms on protein structure: how good are we at identifying likely disease associated mutations? Proceedings of "Molecular Interactions - Bringing Chemistry to Life." 2006. pp 11-26.
22. Delano WL. The PyMOL molecular graphics system. Palo Alto, CA: DeLano Scientific; 2002.
23. Knauth K, Bex C, Jemth P, Buchberger A. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1α interactions. Oncogene 2006;25:370-377. (Pubitemid 43117622)
24. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang G-W, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741. (Pubitemid 30687077)
25. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Contrasting effects of HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-1038.
26. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-10435. (Pubitemid 30707283)
27. Roe J-S, Kim H, Lee S-M, Kim S-T, Cho E-J, Youn H-D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006;22:395-404.
28. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway is renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-1958.
29. Kawasaki T, Bilim V, Takahashi K, Tomita Y. Infrequent alteration of p53 pathway in metastatic renal cell carcinoma. Oncol Rep 1999;6:329-333.
30. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-553.
31. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG, Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-1027. (Pubitemid 32447779)
32. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Jr, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155-167. (Pubitemid 41132744)
33. Schoenfeld AR, Davidowitz EJ, Burk RD. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci USA 2000;97:8507-8512.
34. Duan DR, Humphrey JS, Chen DYT, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, Klausner RD. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995;92:6459-6463.